Related Experiment Video

Updated: Feb 25, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy

S Liu1, J Zha2, M Lei2

  • 1Department of Ultrasound, The People's Hospital of Three Gorges University, The First People's Hospital of Yichang, Yichang, 443000, China. latte201217@163.com.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|August 3, 2017
PubMed
Abstract

Insights

The ERK/MNK/eIF4E pathway is crucial for ovarian cancer chemoresistance. Inhibiting this pathway can enhance chemotherapy effectiveness, offering a new strategy for treating ovarian cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ovarian cancer remains a leading cause of cancer-related deaths globally.
  • Chemotherapy resistance is a major challenge in treating ovarian cancer, leading to poor patient outcomes.
  • Understanding the molecular mechanisms underlying chemoresistance is vital for developing effective therapeutic strategies.

Purpose of the Study:

  • To investigate the role of the Extracellular signal-Regulated Kinase (ERK)/MAPK Interacting Kinase (MNK)/eukaryotic initiation factor 4E (eIF4E) pathway in the development of chemoresistance in ovarian cancer.
  • To determine if targeting the ERK/MNK/eIF4E pathway can sensitize ovarian cancer cells to chemotherapy.

Main Methods:

  • Systematic analysis of phosphorylated ERK, MNK, and eIF4E levels in ovarian cancer patients and cell lines before and after chemotherapy.
  • Utilizing pharmacological inhibitors (e.g., MEK inhibitor U0126) and genetic approaches to investigate the function of the ERK/MNK/eIF4E pathway.
  • Assessing the impact of eIF4E overexpression and depletion on ovarian cancer cell growth, migration, and response to chemotherapeutic agents.

Main Results:

  • Increased phosphorylation of ERK, MNK1, and eIF4E was observed in ovarian cancer cells and patients undergoing chemotherapy, indicating pathway activation.
  • MEK inhibition (U0126) reduced phosphorylation of ERK, MNK1, and eIF4E, confirming Mnk1/eIF4E as downstream effectors of the ERK pathway activated by chemotherapy.
  • Overexpression of eIF4E enhanced ovarian cancer cell growth and conferred resistance to chemotherapy, while eIF4E depletion sensitized cells to chemotherapeutic agents.

Conclusions:

  • Activation of the ERK/MNK/eIF4E signaling pathway is a critical mechanism contributing to chemoresistance in ovarian cancer.
  • Inhibiting the ERK/MNK/eIF4E pathway broadly sensitizes ovarian cancer cells to chemotherapy, suggesting its potential as a therapeutic target.
Keywords:
Chemotherapy resistanceERKMnk/eIF4EOvarian cancer

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.9K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
684
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
741